The Celgene and Pharmstandard-backed immuno-oncology company has raised almost $140m in equity financing in under three years.
US-based immuno-oncology company Jounce has filed to raise up to $75m in an initial public offering on Nasdaq that will provide an exit to pharmaceutical firm Celgene.
Founded in 2012, Jounce is developing immunotherapies that will target a range of the immune system’s cellular components together with non-immune cells in the tumour itself.
Jounce will use the IPO proceeds to advance its lead product candidate, a monoclonal antibody called JTX-2011, through phase I/II trials.
The rest of the proceeds…
